case_images: PMC4532892_01
case_images: PMC4532892_02
case_images: PMC4532892_03
case_images: (a) PET CT before treatment. Arrow shows metabolically active area referring to vulvar lesion. (b) CT correlation. (c) PET CT after treatment.
case_images: CRIOG2015-139817.002.jpg
case_images: PMC4532892_05_CRIOG2015-139817.002.jpg
case_images: fig2
case_images: She is currently being followed by our service on a regular basis and is without evidence of disease recurrence over 4 years after primary treatment (see Figure 2).
case_images: PMC4532892_04
case_images: EGFR immunostain with cytoplasmic staining. The brown staining shows where the EGFR is detected.
case_images: CRIOG2015-139817.001.jpg
case_images: PMC4532892_04_CRIOG2015-139817.001.jpg
case_images: fig1
case_images: Our patient was determined to have FIGO stage IIIB squamous cell carcinoma of the vulva (see Figure 1). Given our concern for the high risk of recurrence, the patient's primary tumor was tested and noted to be epidermal growth factor receptor (EGFR) positive (see Figure 1).
case_images: PMC4532892_05
case_images: (a) PET CT before treatment. Arrow shows metabolically active area referring to vulvar lesion. (b) CT correlation. (c) PET CT after treatment.
case_images: CRIOG2015-139817.002.jpg
case_images: PMC4532892_05_CRIOG2015-139817.002.jpg
case_images: fig2
case_images: She is currently being followed by our service on a regular basis and is without evidence of disease recurrence over 4 years after primary treatment (see Figure 2).